LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) Demonstrated Superior Progression-Free Survival (PFS) and Overall Survival (OS) Versus Sunitinib as First-Line Treatment for Patients With Advanced Renal Cell Carcinoma
LENVIMA Plus KEYTRUDA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib, With a Median PFS of Nearly Two Years Versus Nine Months for Sunitinib
LENVIMA Plus Everolimus Significantly Improved PFS and Objective Response Rate Versus Sunitinib
First Results From Pivotal CLEAR Study (Study 307/KEYNOTE-581) Presented at 2021 Genitourinary Cancers Symposium (ASCO GU) and Published in the New England Journal of Medicine
TOKYO, Feb 15, 2021 - (JCN Newswire) - Eisai Co., Ltd. and Merck & Co., Inc., Kenilworth, N.J., U.S.A. (known as MSD outside the United States and Canada) today announced the first presentation of new investigational data from the pivotal Phase 3 CLEAR study (Study 307/KEYNOTE-581) in an oral presentation session (Abstrac
Janssen: Behandlung mit ERLEADA®▼(Apalutamid) bewirkt signifikant verbessertes Gesamtüberleben bei P
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.
Janssen Pharmaceutica NV: Janssen: Behandlung mit ERLEADA?(Apalutamid) bewirkt signifikant verbessertes Gesamtüberleben bei Patienten mit metastasiertem hormonsensitivem Prostatakarzinom
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.